We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our planet. But are those connections working for or against your… ...

Biogen has entered into an agreement with TJ Biopharma (TJ Bio) to acquire exclusive rights to felzartamab in the Greater China region, further extending its control of the investigational therapy to ...

Veradermics has announced positive topline results from its open-label phase 2 clinical trial (Study ‘207’) evaluating ...

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each ...

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with ...

Independent healthcare communications consultancy POP Health has appointed Stephanie O’Hagan as Senior Director. O’Hagan has ...

AstraZeneca has entered into an exclusive licence agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel ...

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of ...

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain ...

The phrase "patient-centered care" is tossed around freely in healthcare corporate boardrooms. Yet, for more than half the ...

Bristol Myers Squibb’s New Drug Application (NDA) for mezigdomide has been accepted by the US FDA. Mezigdomide is an oral ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal worth around $10.0bn. Crinetics is a global ...